1. In Vivo

Hospitals' Hang-Ups With Point-Of-Care Testing

The hospital market for point-of-care testing represents a conundrum for manufacturers. Demand for it is growing--but, with the exception of glucose monitoring, not as fast as proponents had expected. A recent survey of a third of US hospitals with 150 or more beds seeks to gather information about hospital point-of-care testing utilization and preferences.

The hospital point-of-care testing (POCT) market presents a conundrum for manufacturers. Demand for it is growing—but not as fast as many proponents of the field expected. The premise—easy-to-use tests performed near the patient will improve test result turnaround time and thus clinical decision-making and ultimately outcomes—is sound. But finding the right technology and applications in which a rapid test result is worth the trade-off of higher cost and more labor has been a challenge.

That's among the conclusions of a survey conducted this summer by a Stamford, CT-based consulting firm highlighting the prospects for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.